Durable Remission After Aggressive Chemotherapy for Very Late Post–Kidney Transplant Lymphoproliferation: A Report of 16 Cases Observed in a Single Center

Mamzer-Bruneel, Marie-France; Lome, Carmen; Morélon, Emmanuel; Lévy, Vincent; Bourquelot, Priscille; Jacobs, Frédéric; Gessain, Antoine; Intyre, E Mac; Brousse, Nicole; Kreis, Henri; Hermine, Olivier

doi:10.1200/jco.2000.18.21.3622

Cited by 84 publications

(49 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haematologica 2007; 92: [273][274] Chemotherapy is effective in PTLD, but is associated with significant toxicity, including substantial treatmentrelated mortality (TRM). Reports of chemotherapy in PTLD are generally based on small cohorts, including patients with a broad spectrum of different subtypes of PTLD, and heterogeneous chemotherapy regimens, [1][2][3][4][5][6][7] ( Table 1, online version only). A large retrospective analysis, however, has demonstrated improved overall survival (OS) with multidrug regimens compared with single-agent chemotherapy in PTLD.…”

Section: Chop-21 For the Treatment Of Post-transplant Lymphoproliferamentioning

confidence: 99%

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

Choquet¹,

Trappe²,

Leblond³

et al. 2007

Haematologica

142

View full text Add to dashboard Cite

Section: Chop-21 For the Treatment Of Post-transplant Lymphoproliferamentioning

confidence: 99%

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

Choquet¹,

Trappe²,

Leblond³

et al. 2007

Haematologica

142

View full text Add to dashboard Cite

“…While chemotherapy may occasionally provide long-term relapse-free survival, it is accompanied by a high infection and mortality rate (Table 3e). 48,49 Anti-B cell antibodies A promising therapeutic option to control B-cell proliferation is anti-B-cell antibody therapy. Expression of B-cell antigens is variable in PTLD, most likely because of the dysregulation by EBV infection.…”

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

Post-transplant lymphoproliferative disorder: a review

Loren

Porter

Stadtmauer

et al. 2003

Bone Marrow Transplant

246

201

View full text Add to dashboard Cite

Summary:Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of Epstein-Barr virus-related (EBV) clinical diseases, from a benign mononucleosis-like illness to a fulminant non-Hodgkin's lymphoma. In the setting of hematopoietic stem cell transplantation, PTLD is an often-fatal complication occurring relatively early after transplant. Risk factors for the development of PTLD are well established, and include HLA-mismatching, T-cell depletion, and the use of antilymphocyte antibodies as conditioning or treatment of graft-versushost disease. Early recognition of PTLD is particularly important in the SCT setting, because PTLD in these patients tends to be rapidly progressive. Familiarity with the clinical features of PTLD and a heightened level of suspicion are critical for making the diagnosis. Surveillance techniques with EBV antibody titers and/or polymerase chain raction (PCR) may have a role in some highrisk settings. Immune-based therapies such as monoclonal anti-B-cell antibodies, interferon-a, and EBV-specific donor T cells, either as treatment for PTLD or as prophylaxis in high-risk patients, represent promising new directions in the treatment of this disease.

show abstract

“…For patients who do not respond to rituximab chemotherapy, lymphoma-like regimens have been used [5,8]. Radiation is used for localized disease or for palliation.…”

Section: Discussionmentioning

confidence: 99%

Mini‐BEAM and autologous hematopoietic stem‐cell transplant for treatment of post‐transplant lymphoproliferative disorders

et al. 2005

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of lymphoid proliferative diseases seen as result of immunosuppression in recipients of solid organ or hematopoietic stem-cell transplantation. Options of treatment include reduction or discontinuation of immunosuppressive agents, antiviral drugs, rituximab, chemotherapy, and radiation. We report two unique cases of PTLD (CNS and plasmacytoma-like) treated successfully with salvage chemotherapy, mini-BEAM chemotherapy, and autologous stem-cell transplant. In both cases, patients were also treated with sirolimus and prednisone as immunosuppression, and neither patient rejected their solid organ transplants. With over 30 months of follow-up, both patients remain in complete remission with excellent allograft function. Am.

show abstract

Durable Remission After Aggressive Chemotherapy for Very Late Post–Kidney Transplant Lymphoproliferation: A Report of 16 Cases Observed in a Single Center

Cited by 84 publications

References 27 publications

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

Post-transplant lymphoproliferative disorder: a review

Mini‐BEAM and autologous hematopoietic stem‐cell transplant for treatment of post‐transplant lymphoproliferative disorders

Contact Info

Product

Resources

About